(Q38090664)

28 August 2017

Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition (English)

1 reference

28 August 2017

Ac Backes

1

1 reference

28 August 2017

B Zech

2

1 reference

28 August 2017

B Felber

3

1 reference

28 August 2017

B Klebl

4

1 reference

28 August 2017

G Müller

5

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

Expert Opinion on Drug Discovery

28 August 2017

1 reference

28 August 2017

3

1 reference

28 August 2017

12

1 reference

28 August 2017

1427-1449

1 reference

A Src-like inactive conformation in the abl tyrosine kinase domain

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Crystal structure of the tyrosine kinase domain of the human insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Sensing extracellular matrix: an update on discoidin domain receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A general strategy for creating "inactive-conformation" abl inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

NMR characterization of kinase p38 dynamics in free and ligand-bound forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Recent progress in development of non-ATP competitive small-molecule inhibitors of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Discovery and characterization of a substrate selective p38alpha inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

A myristoyl/phosphotyrosine switch regulates c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Structural basis for the autoinhibition of c-Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460440802580106

10.1517/17460440802580106

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference